**Conflict of interest EMAS board members**

Conflicts of interest (COI) arise where there is a divergence between an individual's responsibilities to the EMAS Board and their other interests, such that an individual's motives might be compromised, or perceived to be compromised.

COI include, but are not limited to, the following. Board members are required to disclose any of the following:

1. All relevant financial relationships with commercial interests (entities producing, marketing, re-selling, or distributing goods or services) in any amount as well as the nature of the relationship (personal or immediate family) within the past 5 years eg Grant/research support
   Consultancies
   Membership of speakers' bureaux
   Patent ownership
   Membership of board of directors
   Stock shareholding
   Other financial support

2. Any non-financial relationships/affiliations relevant to EMAS

☐ I have no potential conflict of interest to report

☒ I have the following potential conflict(s) of interest to report:

- Participated as an expert at a board meeting by Wellfor in 2015
- Participated at an expert group meeting by Gedeon Richter in 2017
- Principle investigator in clinical trials by ITF Research Pharma
- Principle investigator in a clinical trial by Diurnal Limited
- Principle investigator in a clinical trial by Merck
- Principle investigator in a clinical trial by Asarina Pharma
- Received honoraria from Novo Nordisk, Gedeon Richter, Campus Pharma, Ferring and Exeltis for different lectures
Angelica Lindén Hirschberg

Name ....................................................

Signed ............................................

Date ................ February 22, 2019